Compare Five9 Inc (FIVN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Nuwellis Inc — how do they compare? Five9 Inc trades at $36.22 (market cap $2.63B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Five9 Inc is far larger — about 1195.5× Nuwellis Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Nuwellis Inc for 26 Days on average.
| FIVN | NUWE | |
|---|---|---|
Market Cap | $2.63B | $2.20M |
Volume | 1,864,393 | 121,544 |
Sector | Technology | Health |
52-Week High | $38.65 | $146.65 |
52-Week Low | $13.61 | $0.68 |
Typical Hold Time | 72 Days | 26 Days |
Enterprise Value | $2.78B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $36.4, up 7.76% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue growth is accelerating, reaching $1.15B in 2025, while net income turned positive at $39.42M. The stock is near its 52-week high, supported by strong AI-driven subscription growth and leadership in the contact center-as-a-service market.
Outlook remains positive given robust AI revenue growth and raised guidance, but risks include high valuation multiples and insider selling. Analyst consensus is bullish with a $34 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further upside.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
